1. Home
  2. MREO vs HTBI Comparison

MREO vs HTBI Comparison

Compare MREO & HTBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • HTBI
  • Stock Information
  • Founded
  • MREO 2015
  • HTBI 1926
  • Country
  • MREO United Kingdom
  • HTBI United States
  • Employees
  • MREO N/A
  • HTBI 565
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • HTBI Savings Institutions
  • Sector
  • MREO Health Care
  • HTBI Finance
  • Exchange
  • MREO Nasdaq
  • HTBI Nasdaq
  • Market Cap
  • MREO 577.6M
  • HTBI 660.9M
  • IPO Year
  • MREO N/A
  • HTBI 2012
  • Fundamental
  • Price
  • MREO $3.68
  • HTBI $37.44
  • Analyst Decision
  • MREO Strong Buy
  • HTBI Buy
  • Analyst Count
  • MREO 4
  • HTBI 4
  • Target Price
  • MREO $7.50
  • HTBI $37.67
  • AVG Volume (30 Days)
  • MREO 769.7K
  • HTBI 51.7K
  • Earning Date
  • MREO 11-12-2024
  • HTBI 10-24-2024
  • Dividend Yield
  • MREO N/A
  • HTBI 1.28%
  • EPS Growth
  • MREO N/A
  • HTBI 14.18
  • EPS
  • MREO N/A
  • HTBI 3.52
  • Revenue
  • MREO $1,000,000.00
  • HTBI $187,440,000.00
  • Revenue This Year
  • MREO $16.39
  • HTBI N/A
  • Revenue Next Year
  • MREO $9.44
  • HTBI N/A
  • P/E Ratio
  • MREO N/A
  • HTBI $10.53
  • Revenue Growth
  • MREO N/A
  • HTBI 2.84
  • 52 Week Low
  • MREO $1.86
  • HTBI $22.44
  • 52 Week High
  • MREO $5.02
  • HTBI $38.62
  • Technical
  • Relative Strength Index (RSI)
  • MREO 39.84
  • HTBI 61.96
  • Support Level
  • MREO $3.18
  • HTBI $36.52
  • Resistance Level
  • MREO $4.40
  • HTBI $37.74
  • Average True Range (ATR)
  • MREO 0.24
  • HTBI 1.11
  • MACD
  • MREO -0.06
  • HTBI 0.12
  • Stochastic Oscillator
  • MREO 41.39
  • HTBI 81.45

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About HTBI HomeTrust Bancshares Inc.

HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.

Share on Social Networks: